Sorin's Paradym 8770 sonR cardiac resynchronisation defibrillator:
This article was originally published in Clinica
Sorin has CE marked its Paradym 8770 sonR cardiac resynchronisation therapy defibrillator (CRT-D) for sale in Europe. The system employs sonR technology, a sensor that adjusts CRT delivery based on haemodynamic response - as opposed to conventional CRT-D devices which monitor the electrical activity of the heart. The Milan, Italy-based company claims that Paradym sonR is the first device delivering continuous management of resynchronisation therapy during heart failure patients' everyday life. Sorin's cardiac rhythm management business has also initiated a 150-patient European clinical trial of the device. According to the European Society of Cardiology (ESC) and the American Heart Association (AHA), more than 10 million Europeans and five million Americans suffer from heart failure.
You may also be interested in...
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.